A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19 Infection
Veyonda® in combination with standard care in patients hospitalised with moderate COVID-19 disease.
Objectives - to demonstrate that in COVID-19 patients were at risk of developing a cytokine storm and septic shock:
- Veyonda was safe and well tolerated, and
- Veyonda could halt the deterioration of COVID-19 patients and progression to septic shock
The novel and unique anti-inflammatory action of Veyonda, via the STING signaling pathway, could potentially prevent progression of COVID-19 disease.
The aim was to prevent the onset of the cytokine storm that inflicts tissue damage in the lungs and other major organs, aggravating lung damage and requiring mechanical ventilation and potentially causing death.
There is potential that this activity could extend to other causes of septic shock.
A Phase 1 dose-escalation and dose-expansion study focused on safety and proof-of-principle endpoints (biomarker and clinical responses).
Patients who had been admitted to hospital for respiratory insufficiency (not requiring artificial ventilation) associated with the SARS-CoV-2 virus were recruited and treated for 14 days.